Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0113-6856 · 1 trial · 2 indications
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| NNC0113-6856 (Oral Cohort) | EXPERIMENTAL | Participants will receive single oral dose of NNC0113-6856 tablets in dose escalated manner. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive single oral dose of placebo (NNC0113-6856) tablets in dose escalated manner. |
| NNC0113-6856 (i.v. Cohort) | EXPERIMENTAL | Participants will receive single dose of 1.5 milligrams (mg) NNC0113-6856 intravenously (i.v.). |
| Name | Type | Description |
|---|---|---|
| NNC0113-6856 | DRUG | Participants will receive NN0113-6856 orally or intravenously. |
| Placebo | DRUG | Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts. |
Inclusion Criteria: * Male. * Aged 18-55 years (both inclusive) at the time of signing informed consent. * Body mass index between 20.0 and 27.0 kilogram per meter square (kg/m\^2)(both inclusive). Exclusion Criteria: * Glycated haemoglobin (HbA1c) greater than or equal to (\>=) 6.5 percent (%) (...
Top 16 of 30 competitors
NNC0113-6856 is an investigational small molecule medicine being developed by Novo Nordisk for Type 2 Diabetes. It is in Phase 1 clinical development and has been studied in a single completed trial conducted in Germany. It is not an approved therapy.
NNC0113-6856 is being developed as a treatment for Type 2 Diabetes. The completed Phase 1 study enrolled healthy male volunteers and listed Type 2 Diabetes among its conditions. The program remains in early clinical development, so the drug is not available as a prescribed treatment.
NNC0113-6856 is developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the Phase 1 study of the compound. No partner or licensing arrangement for this asset is disclosed.
NNC0113-6856 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The compound is investigational and has not been approved by the FDA or any other regulator based on the available information.
NNC0113-6856 has been evaluated in one completed Phase 1 trial, NCT05521256, titled A Research Study of a New Medicine NNC0113-6856 in Healthy Males. The trial enrolled 70 participants in Germany, was randomized, double blind, and placebo controlled, and included only males aged 18 years and older.
Yes, NNC0113-6856 is a small molecule. It is being developed by Novo Nordisk as an oral-style small molecule candidate for Type 2 Diabetes, and it has completed one Phase 1 trial in healthy male volunteers. No later-stage trials are currently active.